162 related articles for article (PubMed ID: 8290386)
1. Effect of the nonsteroidal antiandrogen nilutamide on adrenal androgen secretion.
Decensi A; Torrisi R; Marroni P; Pensa F; Padovani P; Boccardo F
Prostate; 1994; 24(1):17-23. PubMed ID: 8290386
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer.
Bélanger A; Dupont A; Labrie F
J Clin Endocrinol Metab; 1984 Sep; 59(3):422-6. PubMed ID: 6086697
[TBL] [Abstract][Full Text] [Related]
3. Prolactin has a direct effect on adrenal androgen secretion.
Higuchi K; Nawata H; Maki T; Higashizima M; Kato K; Ibayashi H
J Clin Endocrinol Metab; 1984 Oct; 59(4):714-8. PubMed ID: 6090494
[TBL] [Abstract][Full Text] [Related]
4. Mild adrenal and ovarian steroidogenic abnormalities in hirsute women without hyperandrogenemia: does idiopathic hirsutism exist?
Escobar-Morreale HF; Serrano-Gotarredona J; García-Robles R; Sancho J; Varela C
Metabolism; 1997 Aug; 46(8):902-7. PubMed ID: 9258272
[TBL] [Abstract][Full Text] [Related]
5. Effects of aging on adrenal function in the human: responsiveness and sensitivity of adrenal androgens and cortisol to adrenocorticotropin in premenopausal and postmenopausal women.
Parker CR; Slayden SM; Azziz R; Crabbe SL; Hines GA; Boots LR; Bae S
J Clin Endocrinol Metab; 2000 Jan; 85(1):48-54. PubMed ID: 10634362
[TBL] [Abstract][Full Text] [Related]
6. The effects of spironolactone on adrenal steroidogenesis in hirsute women.
Serafini P; Lobo RA
Fertil Steril; 1985 Nov; 44(5):595-9. PubMed ID: 2996951
[TBL] [Abstract][Full Text] [Related]
7. Control of adrenal androgen production.
Odell WD; Parker LN
Endocr Res; 1984-1985; 10(3-4):617-30. PubMed ID: 6100259
[TBL] [Abstract][Full Text] [Related]
8. The effect of serum prolactin on plasma adrenal androgens and the production and metabolic clearance rate of dehydroepiandrosterone sulfate in normal and hyperprolactinemic subjects.
Schiebinger RJ; Chrousos GP; Cutler GB; Loriaux DL
J Clin Endocrinol Metab; 1986 Jan; 62(1):202-9. PubMed ID: 2999177
[TBL] [Abstract][Full Text] [Related]
9. [Combined anti-androgen treatment in adenocarcinoma of the prostate: first use of a new therapeutically efficacious principle in hormone-dependent cancer].
Labrie F; Dupont A; Bélanger A; Lacourcière Y; Monfette JE; Monfette G
Ann Urol (Paris); 1986; 20(2):98-106. PubMed ID: 2940959
[TBL] [Abstract][Full Text] [Related]
10. Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.
Harris MG; Coleman SG; Faulds D; Chrisp P
Drugs Aging; 1993; 3(1):9-25. PubMed ID: 8453188
[TBL] [Abstract][Full Text] [Related]
11. Ovine prolactin potentiates the action of adrenocorticotropic hormone on the secretion of dehydroepiandrosterone sulfate and dehydroepiandrosterone from cultured bovine adrenal cells.
Higuchi K; Nawata H; Kato K; Ibayashi H
Horm Metab Res; 1985 Sep; 17(9):451-3. PubMed ID: 2995221
[TBL] [Abstract][Full Text] [Related]
12. The pure antiandrogen RU 23908 (Anandron), a candidate of choice for the combined antihormonal treatment of prostatic cancer: a review.
Raynaud JP; Bonne C; Moguilewsky M; Lefebvre FA; Bélanger A; Labrie F
Prostate; 1984; 5(3):299-311. PubMed ID: 6374639
[TBL] [Abstract][Full Text] [Related]
13. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
[TBL] [Abstract][Full Text] [Related]
14. Androgens, adrenal androgen precursors, and their metabolism in untreated primary tumors and lymph node metastases of human prostatic cancer.
Klein H; Bressel M; Kastendieck H; Voigt KD
Am J Clin Oncol; 1988; 11 Suppl 2():S30-6. PubMed ID: 2853935
[TBL] [Abstract][Full Text] [Related]
15. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens.
Labrie F; Dupont A; Belanger A; Lacoursiere Y; Raynaud JP; Husson JM; Gareau J; Fazekas AT; Sandow J; Monfette G
Prostate; 1983; 4(6):579-94. PubMed ID: 6415630
[TBL] [Abstract][Full Text] [Related]
16. The effect of growth hormone replacement therapy on adrenal androgen secretion in adult onset hypopituitarism.
Isidori AM; Kaltsas GA; Perry L; Burrin JM; Besser GM; Monson JP
Clin Endocrinol (Oxf); 2003 May; 58(5):601-11. PubMed ID: 12699442
[TBL] [Abstract][Full Text] [Related]
17. Flutamide suppresses adrenal steroidogenesis but has no effect on insulin resistance and secretion and lipid levels in overweight women with polycystic ovary syndrome.
Vrbíková J; Hill M; Dvoráková K; Stanická S; Vondra K; Stárka L
Gynecol Obstet Invest; 2004; 58(1):36-41. PubMed ID: 15087595
[TBL] [Abstract][Full Text] [Related]
18. Adrenal and ovarian steroid hormone responses to gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome.
Gonzalez F; Hatala DA; Speroff L
Am J Obstet Gynecol; 1991 Sep; 165(3):535-45. PubMed ID: 1832519
[TBL] [Abstract][Full Text] [Related]
19. Long-term administration of gonadotropin-releasing hormone agonist and dexamethasone: assessment of the adrenal role in ovarian dysfunction.
Cedars MI; Steingold KA; de Ziegler D; Lapolt PS; Chang RJ; Judd HL
Fertil Steril; 1992 Mar; 57(3):495-500. PubMed ID: 1531463
[TBL] [Abstract][Full Text] [Related]
20. Effects of flutamide on pituitary and adrenal responsiveness to corticotrophin releasing factor (CRF).
De Leo V; la Marca A; Lanzetta D; Cariello PL; D'Antona D; Morgante G
Clin Endocrinol (Oxf); 1998 Jul; 49(1):85-9. PubMed ID: 9797851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
